The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1479
October 12, 2015
View Complete Issue         Table of Contents 2019 
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
October 12, 2015 (Issue: 1479)
The FDA has approved daclatasvir (Daklinza – BMS), an oral direct-acting antiviral drug, for use with sofosbuvir (Sovaldi) for treatment of chronic hepatitis C virus (HCV) genotype 3 infection. Daclatasvir is the first drug approved for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Daclatasvir (Daklinza) for HCV Genotype 3 Infection
Article code: 1479c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.